| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SDC2 |
| Uniprot No | P34741 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-130aa |
| 氨基酸序列 | LDNSSIEEASGVYPIDDDDYASASGSGADEDVESPELTTSRPLPKILLTS AAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERKMDPAEEDTNV |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SDC2(Syndecan-2)重组蛋白的3篇代表性文献示例(注：具体文献需通过学术数据库验证，以下为模拟内容)：
---
1. **文献名称**: *"Recombinant Syndecan-2 Ectodomain Attenuates Breast Cancer Metastasis by Inhibiting Fibroblast Growth Factor Signaling"*
**作者**: Lee H, et al.
**摘要**: 该研究通过表达并纯化重组SDC2胞外域蛋白，发现其可通过竞争性结合FGF2抑制乳腺癌细胞的迁移和侵袭，揭示了其在靶向肿瘤微环境中的治疗潜力。
2. **文献名称**: *"Structural Characterization of Recombinant Human Syndecan-2 and Its Role in Wnt/β-Catenin Pathway Activation"*
**作者**: Zhang Y, et al.
**摘要**: 作者利用X射线晶体学解析了重组人SDC2的胞外结构域，证明其通过结合Wnt蛋白增强β-catenin信号通路，为开发基于SDC2的癌症干预策略提供结构基础。
3. **文献名称**: *"Recombinant Syndecan-2 as a Serum Biomarker for Early Detection of Colorectal Cancer"*
**作者**: Kim S, et al.
**摘要**: 该研究开发了高灵敏度的重组SDC2检测方法，发现其在结直肠癌患者血清中显著升高，提示其作为早期诊断生物标志物的潜力。
---
**建议**：可通过PubMed或Google Scholar以关键词 **"recombinant syndecan-2"、"SDC2 recombinant protein"** 检索最新文献，重点关注《Journal of Biological Chemistry》《Cancer Research》等期刊。部分研究可能涉及重组SDC2在炎症、纤维化或再生医学中的应用。
SDC2 (Syndecan-2) is a transmembrane heparan sulfate proteoglycan belonging to the syndecan family, which plays pivotal roles in cell-matrix interactions, cell adhesion, and signal transduction. Structurally, it consists of an extracellular domain modified with glycosaminoglycan (GAG) chains, a single transmembrane domain, and a short cytoplasmic tail that interacts with cytoskeletal and signaling molecules. SDC2 is broadly expressed in epithelial and endothelial cells, where it regulates processes like wound healing, angiogenesis, and immune responses by binding growth factors (e.g., FGF2. VEGF) and extracellular matrix components.
Dysregulation of SDC2 is implicated in pathologies including cancer, fibrosis, and inflammatory diseases. In oncology, SDC2 exhibits dual roles: it suppresses tumorigenesis in colorectal cancer by modulating Wnt/β-catenin signaling but promotes metastasis in breast and lung cancers through interactions with integrins and matrix metalloproteinases. These context-dependent functions make SDC2 a compelling therapeutic target.
Recombinant SDC2 proteins, typically produced in mammalian or insect cell systems to preserve post-translational modifications, are essential tools for studying its biological mechanisms. They enable structural analysis of ligand-binding domains, screening for therapeutic inhibitors, and exploration of its role in extracellular vesicle-mediated communication. Recent studies also highlight its potential as a diagnostic biomarker; for instance, SDC2 methylation in circulating DNA is a promising non-invasive indicator for early colorectal cancer detection. Challenges remain in fully elucidating its signaling networks and tissue-specific functions, but recombinant SDC2 continues to drive advances in understanding cell microenvironment dynamics and developing precision therapies.
×
